Cartel J L, Spiegel A, Nguyen L, Moulia-Pelat J P, Martin P M, Roux J F
Institut Territorial de Recherches Médicales Louis Malardé, Tahiti, Polynésie Française.
Rev Epidemiol Sante Publique. 1992;40(5):307-12.
A double blind randomized trial was performed on 58 healthy Polynesian Wuchereria bancrofti carriers, they were randomly allocated to treatments with repeated annual or semi-annual doses of ivermectin 100 mcg/kg or diethylcarbamazine (DEC) 3 mg/kg, or with repeated annual doses of DEC 6 mg/kg. After the 12-month treatment, the clearance of microfilaremia was complete in 7 of the 23 carriers treated with ivermectin and in 3 of the 35 treated with DEC. Nine months after that treatment, the lowest mean microfilaremia was observed in the carriers treated with 3 successive semi-annual doses of DEC 3 mg/kg. Adverse reactions were comparable in carriers treated with ivermectin and in those treated with DEC, and did not interfere with daily activities of treated subjects.
对58名健康的波利尼西亚班氏吴策线虫携带者进行了一项双盲随机试验，他们被随机分配接受以下治疗：每年或每半年重复给予100微克/千克的伊维菌素，或3毫克/千克的乙胺嗪（DEC），或每年重复给予6毫克/千克的DEC。经过12个月的治疗后，在接受伊维菌素治疗的23名携带者中有7名微丝蚴血症完全清除，在接受DEC治疗的35名携带者中有3名完全清除。在该治疗9个月后，在接受连续3次每半年3毫克/千克DEC治疗的携带者中观察到最低的平均微丝蚴血症。接受伊维菌素治疗的携带者和接受DEC治疗的携带者的不良反应相当，且不影响治疗对象的日常活动。
